What sector does Anthem Biosciences Ltd belong to?

Anthem Biosciences Ltd operates in the Healthcare sector, specifically the Biotechnology industry, and is listed on the NSE.

What is the current share price of ANTHEM?

As of the latest available quote, ANTHEM traded at ₹940.90. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of ANTHEM?

Anthem Biosciences Ltd has a price-to-earnings (P/E) ratio of about 92.61. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of ANTHEM?

The market capitalisation of Anthem Biosciences Ltd is approximately ₹53,005 Cr.

Is Anthem Biosciences Ltd profitable?

For its latest reported financial year, Anthem Biosciences Ltd recorded a net profit margin of about 27.87%.

Does ANTHEM pay a dividend?

Anthem Biosciences Ltd does not currently show a dividend yield in our data.

What is the return on equity (ROE) of ANTHEM?

Anthem Biosciences Ltd has a return on equity (ROE) of about 22.30%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of ANTHEM?

Over the past 52 weeks, ANTHEM has traded between a low of ₹579.15 and a high of ₹977.55.

Anthem Biosciences Ltd

ANTHEM NSE Healthcare Biotechnology

Nifty 500 Midcap 150 LargeMid 250

₹940.90

-0.15%

Delayed · cached 15 min

Fair value analysis

ANTHEM

Anthem Biosciences Ltd

₹942.30

Close used for this calculation

₹357.41Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

58/100

Profitability23/25

Returns8/25

Balance Sheet21/25

Efficiency6/25

Growth9/25

Good

Quality radar

Consensus fair value

₹357.41

Above FV

▼ -62.1% against the close used

Model range ₹113.42 – ₹580.23

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹113.42Fair value₹357.41Bull₹580.23

FairClose

52-week traded range

52W low ₹592.4052W high ₹957.80

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Anthem Biosciences Ltd closed at ₹942.30, 163.6% above the consensus fair value of ₹357.41 drawn from 8 valuation models.

Financial DNA score 58/100 — Good. P/E of 89.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹224.78

-76.1%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹113.42

-88.0%

√(22.5 × EPS × BVPS)

EPS=10.54, BVPS=54.25 · outside Graham range (P/E 89.3, P/B 17.4) — asset-light, treat as a rough floor

P/E Fair Value

₹580.23

-38.4%

EPS × 55.05x (sector P/E)

EPS=10.54, Sector P/E=55.05x

Peter Lynch (PEG)

₹168.64

-82.1%

EPS × Growth% (PEG = 1 is fair)

EPS=10.54, g=16%

EV/EBITDA

₹308.80

-67.2%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=9.68B

Book Value (P/B)

₹221.06

-76.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=54.25, ROE=22.3%, g=6%, r=10%

Reverse DCF

₹942.30

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 27.6% | Historical: 16%

Margin of Safety

₹229.61

-75.6%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=306.14, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer